206 related articles for article (PubMed ID: 25313908)
1. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
2. Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.
Ooms AH; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Huff V; Dome JS; Chi YY; Tian J; Geller JI; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Walz AL; van den Heuvel-Eibrink MM; de Krijger RR; Ross N; Gastier-Foster JM; Perlman EJ
Clin Cancer Res; 2016 Nov; 22(22):5582-5591. PubMed ID: 27702824
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.
Williams RD; Al-Saadi R; Natrajan R; Mackay A; Chagtai T; Little S; Hing SN; Fenwick K; Ashworth A; Grundy P; Anderson JR; Dome JS; Perlman EJ; Jones C; Pritchard-Jones K
Genes Chromosomes Cancer; 2011 Dec; 50(12):982-95. PubMed ID: 21882282
[TBL] [Abstract][Full Text] [Related]
4. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
6. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of p53 proteins in Wilms' tumour: a possible association with the histological prognostic parameter of anaplasia.
Cheah PL; Looi LM; Chan LL
Histopathology; 1996 Jan; 28(1):49-54. PubMed ID: 8838120
[TBL] [Abstract][Full Text] [Related]
8. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.
Natrajan R; Little SE; Sodha N; Reis-Filho JS; Mackay A; Fenwick K; Ashworth A; Perlman EJ; Dome JS; Grundy PE; Pritchard-Jones K; Jones C
J Pathol; 2007 Jan; 211(1):52-9. PubMed ID: 17103382
[TBL] [Abstract][Full Text] [Related]
9. A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.
Uno K; Rastegar B; Jansson C; Durand G; Valind A; Chattopadhyay S; Bertolotti A; Ciceri S; Spreafico F; Collini P; Perotti D; Mengelbier LH; Gisselsson D
Mod Pathol; 2024 Jan; 37(1):100382. PubMed ID: 37951357
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of preoperatively treated patients with anaplastic Wilms tumors registered in the UK SIOP-WT-2001 and IMPORT study cohorts (2002-2020).
Vujanić GM; Mifsud W; Chowdhury T; Al-Saadi R; Pritchard-Jones K;
Cancer; 2022 Apr; 128(8):1666-1675. PubMed ID: 35119702
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of nuclear unrest and p53 immunostaining in Wilms' tumor.
Salama A; Kamel A
J Egypt Natl Canc Inst; 2011 Mar; 23(1):31-9. PubMed ID: 22099934
[TBL] [Abstract][Full Text] [Related]
12. Bilateral wilms tumor with TP53-related anaplasia.
Popov SD; Vujanic GM; Sebire NJ; Chagtai T; Williams R; Vaidya S; Pritchard-Jones K
Pediatr Dev Pathol; 2013; 16(3):217-23. PubMed ID: 23387809
[TBL] [Abstract][Full Text] [Related]
13. Association of TP53 polymorphisms on the risk of Wilms tumor.
Andrade RC; Cardoso LC; Ferman SE; Faria PS; Seuánez HN; Achatz MI; Vargas FR
Pediatr Blood Cancer; 2014 Mar; 61(3):436-41. PubMed ID: 24038938
[TBL] [Abstract][Full Text] [Related]
14. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
15. Resolving the Pathogenesis of Anaplastic Wilms Tumors through Spatial Mapping of Cancer Cell Evolution.
Rastegar B; Andersson N; Petersson A; Karlsson J; Chattopadhyay S; Valind A; Jansson C; Durand G; Romerius P; Jirström K; Holmquist Mengelbier L; Gisselsson D
Clin Cancer Res; 2023 Jul; 29(14):2668-2677. PubMed ID: 37140929
[TBL] [Abstract][Full Text] [Related]
16. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
17. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
18. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.
Wegert J; Vokuhl C; Ziegler B; Ernestus K; Leuschner I; Furtwängler R; Graf N; Gessler M
J Pathol Clin Res; 2017 Oct; 3(4):234-248. PubMed ID: 29085664
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
